Chondrial raising $22.6M, gets Friedreich's candidate
Rare disease company Chondrial Therapeutics Inc. (Bala Cynwyd, Pa.) said it is raising up to $22.6 million in a series A led by Deerfield. Wake Forest Innovations' Catalyst Fund, which is managed by Pappas Capital, also participated. The funding is tranched based on undisclosed milestones.
The company also said it had obtained exclusive, worldwide rights to Friedreich's ataxia candidate CTI-1601 from Indiana University Research and Technology Corp. and Wake Forest Innovations, the commercialization arm of Wake Forest Baptist Medical Center...
BCIQ Company Profiles
BCIQ Target Profiles